286 related articles for article (PubMed ID: 11462201)
1. Mortality rates in comparative trials of formulations of amphotericin B.
Frothingham R
Clin Infect Dis; 2001 Aug; 33(4):582-3. PubMed ID: 11462201
[No Abstract] [Full Text] [Related]
2. Controlled trials of amphotericin B lipid complex and other lipid-associated formulations.
Winston DJ; Schiller GJ
Clin Infect Dis; 2000 Jan; 30(1):236-7. PubMed ID: 10619780
[No Abstract] [Full Text] [Related]
3. The experience is CLEAR.
Chandrasekar P
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():31-5. PubMed ID: 16707248
[TBL] [Abstract][Full Text] [Related]
4. ABELCET treatment.
Boyle JA; Swenson CE
J Clin Pharmacol; 1999 Apr; 39(4):427-8. PubMed ID: 10197303
[No Abstract] [Full Text] [Related]
5. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses.
Wingard JR
Bone Marrow Transplant; 1997 Feb; 19(4):343-7. PubMed ID: 9051244
[TBL] [Abstract][Full Text] [Related]
6. Criteria for use of amphotericin B lipid complex injections in adults and children.
Am J Health Syst Pharm; 1996 Nov; 53(22):2751-2. PubMed ID: 9072180
[No Abstract] [Full Text] [Related]
7. Severe and common side-effects of amphotericin B lipid complex (Abelcet).
Ringdén O; Jønsson V; Hansen M; Tollemar J; Jacobsen N
Bone Marrow Transplant; 1998 Oct; 22(7):733-4. PubMed ID: 9818706
[No Abstract] [Full Text] [Related]
8. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
9. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B.
Barcia JP
Pharmacotherapy; 1998; 18(4):874-6. PubMed ID: 9692667
[TBL] [Abstract][Full Text] [Related]
10. An open, non-comparative evaluation of the efficacy and safety of amphotericin B lipid complex as treatment of neutropenic patients with presumed or confirmed pulmonary fungal infections.
Myint H; Kyi AA; Winn RM
J Antimicrob Chemother; 1998 Mar; 41(3):424-6. PubMed ID: 9578177
[No Abstract] [Full Text] [Related]
11. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
12. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
[TBL] [Abstract][Full Text] [Related]
13. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections.
Drew R
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():36-44. PubMed ID: 16713192
[TBL] [Abstract][Full Text] [Related]
14. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
Aguado JM; Lumbreras C; González-Vidal D;
Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
[TBL] [Abstract][Full Text] [Related]
15. Reversible dilated cardiomyopathy related to amphotericin B therapy.
Danaher PJ; Cao MK; Anstead GM; Dolan MJ; DeWitt CC
J Antimicrob Chemother; 2004 Jan; 53(1):115-7. PubMed ID: 14657095
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry.
Pappas PG
Clin Infect Dis; 2005 May; 40 Suppl 6():S379-83. PubMed ID: 15809923
[No Abstract] [Full Text] [Related]
17. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex.
Perfect JR
Clin Infect Dis; 2005 May; 40 Suppl 6():S401-8. PubMed ID: 15809926
[TBL] [Abstract][Full Text] [Related]
18. Use of an amphotericin B lipid complex for treatment of blastomycosis in dogs.
Krawiec DR; McKiernan BC; Twardock AR; Swenson CE; Itkin RJ; Johnson LR; Kurowsky LK; Marks CA
J Am Vet Med Assoc; 1996 Dec; 209(12):2073-5. PubMed ID: 8960189
[TBL] [Abstract][Full Text] [Related]
19. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.
Alexander BD; Dodds Ashley ES; Addison RM; Alspaugh JA; Chao NJ; Perfect JR
Transpl Infect Dis; 2006 Mar; 8(1):13-20. PubMed ID: 16623816
[TBL] [Abstract][Full Text] [Related]
20. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
